| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
An antibody Hs8001 recognizing a metastasis-associated factor was labeled with In-111 and the biodistribution in mice bearing BxPC-3 tumor showed high tumor uptake and low uptake in normal organs. Hs8001 labeled with a positron emitter Zr-89 clearly visualized tumors. The therapeutic efficacy of 90Y-labeled Hs8001 suppressed tumor growth of BxPC-3, whereas the tumor size did not decrease. Next, combination therapy of 90Y-labeled antibody with an anti-cancer drug gemcitabine reduced tumor size. These results suggest that the combination therapy of 90Y-labeled antibody with gemcitabine is a promising therapy for pancreatic cancer. In the present study, we successfully developed a new diagnostic imaging method and a combination therapeutic protocol with 90Y-labeled Hs8001 and gemcitabine.
|
